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A B S T R A C T
In Attention Deficit Hyperactivity Disorder (AD(H)D), treatments using methylphenidate (MPH) and behavioral
interventions like neurofeedback (NF) reflect major therapeutic options. These treatments also ameliorate ex-
ecutive dysfunctions in AD(H)D. However, the mechanisms underlying effects of MPH and NF on executive
functions in AD(H)D (e.g. the ability to inhibit prepotent responses) are far from understood. It is particularly
unclear whether these interventions affect similar or dissociable neural mechanisms and associated functional
neuroanatomical structures. This, however, is important when aiming to further improve these treatments. We
compared the neurophysiological mechanisms of MPH and theta/beta NF treatments on inhibitory control on the
basis of EEG recordings and source localization analyses. The data show that MPH and theta/beta NF both
increase the ability to inhibit pre-potent responses to a similar extent. However, the data suggest that MPH and
NF target different neurophysiological mechanisms, especially when it comes to functional neuroanatomical
structures associated with these effects. Both treatments seem to affect neurophysiological correlates of a
‘braking function’ in medial frontal areas. However, in case of the NF intervention, inferior parietal areas are also
involved. This likely reflects the updating and stabilisation of efficient internal representations in order to in-
itiate appropriate actions. No effects were seen in correlates of perceptual and attentional selection processes.
Notably, reliable effects were only obtained after accounting for intra-individual variability in the neurophy-
siological data, which may also explain the diversity of findings in studies on treatment effects in AD(H)D,
especially concerning neurofeedback.
1. Introduction
Attention Deficit (Hyperactivity) Disorder (AD(H)D) is one of the
most prevalent neuropsychiatric conditions in childhood and is char-
acterised by inattention, hyperactivity and impulsivity (Thomas et al.,
2015). Stimulants and methylphenidate (MPH) in particular are re-
commended as first-line pharmacological treatment (American
Academy of Pediatrics, 2011; Childress and Sallee, 2014; Mattingly
et al., 2017). A large body of evidence shows very good effects of MPH
in terms of AD(H)D symptom reduction (Abikoff et al., 2004; Barkley
et al., 1991; Kratochvil et al., 2002; MTA, 2004; Van der Oord et al.,
2008), academic achievements (Hechtman et al., 2004), quality of life
(Döpfner et al., 2011) and neurocognitive functioning including in-
hibition and the control of impulsive responses (Boonstra et al., 2005;
Broyd et al., 2005; Konrad et al., 2007; Pietrzak et al., 2006; Sevecke
et al., 2006). Particularly the amelioration of inhibitory control deficits
has been associated the dopaminergic actions of MPH (Cubillo et al.,
2014; Nandam et al., 2011; Pauls et al., 2012; Tannock et al., 1989).
Yet, it has also been shown that > 40–60% of patients discontinue this
treatment for several reasons (Duric et al., 2017; Garbe et al., 2012;
Pappadopulos et al., 2009). Even though similar discontinuation rates
have been observed in one non-pharmacological treatment study (Duric
et al., 2017), these treatment approaches are steadily gaining popu-
larity (Dosreis et al., 2017; Ng et al., 2017; Schatz et al., 2015).
Amongst non-pharmacological approaches, neurofeedback (NF) has
gained increasing acceptance and interest. In the case of frequency-
based neurofeedback, cortical activity is recorded from the patient's
head using simple EEG electrodes. The recorded activity (i.e. the power
of neuronal oscillations like theta and beta in the case of frequency-
band NF) is directly fed back to the patients via a simple computer
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game or animation. Even though various limitations and possible con-
founders have been discussed (Cortese et al., 2016; Micoulaud-Franchi
et al., 2015; Sonuga-Barke et al., 2013), many studies including ran-
domized controlled trials have shown that neurofeedback effectively
ameliorates AD(H)D symptoms and associated problems (Arns et al.,
2009; Arns and Strehl, 2013; Bakhshayesh et al., 2011; Baumeister
et al., 2016; Bluschke et al., 2016a; Gevensleben et al., 2010; Holtmann
et al., 2014; Lofthouse et al., 2012; Micoulaud-Franchi et al., 2014,
2015). Neurofeedback approaches have also been shown to increase the
ability to inhibit prepotent responses (Baumeister et al., 2016; Bluschke
et al., 2016a). These positive effects of NF can likely be attributed to the
high relevance of neuronal oscillations for complex cognitive processes
(Cavanagh and Frank, 2014; Cohen, 2014; Helfrich and Knight, 2016;
Hwang et al., 2016; Singer, 2017). In this regard, especially medial
frontal theta oscillations have been demonstrated to reflect an im-
portant mechanism mediating cognitive control (Cavanagh and Frank,
2014). On the symptom level, MPH and NF have directly been com-
pared in its efficacy, but results are contradictory and depend on sample
size, inclusion criteria and study design (Fuchs et al., 2003; Meisel
et al., 2014; Moreno-García et al., 2015; Rossiter and Vaque, 2016).
Yet, the mechanisms underlying positive effects of MPH and NF on
executive functions and inhibitory control in AD(H)D are far from being
understood and it is particularly unclear whether MPH and NF inter-
ventions affect similar or dissociable neural processes and functional
neuroanatomical structures. This, however, is important to further
improve these treatment approaches. The goal of this study is to com-
pare the neurophysiological mechanisms underlying effects of MPH and
theta/beta NF treatment on inhibitory control. We focus on inhibitory
control because this ability is of high clinical relevance in AD(H)D
(Bluschke et al., 2016a; Paul-Jordanov et al., 2010; Pliszka et al., 2007;
Seifert et al., 2003). We compare the cognitive-neurophysiological
changes on the basis of EEG recordings and source localization ana-
lyses, because event-related potential (ERP) correlates of distinct in-
hibitory control subprocesses have been well-described (for review:
Huster et al., 2013). It has repeatedly been shown that a frontal-midline
Nogo-N2 ERP-component reflects pre-motor processes like conflict
monitoring or updating of the response program, while a Nogo-P3 ERP-
component reflects evaluative processing of the successful outcome of
the inhibition (Beste et al., 2011, 2010, 2009; Huster et al., 2013), or
the motor response inhibition itself (Wessel and Aron, 2014).
Considering MPH treatment effects, several studies have reported
significant Nogo-P3 amplitude increases in response inhibition tasks
(Paul-Jordanov et al., 2010; Pliszka et al., 2007; Seifert et al., 2003).
This suggests that neurophysiological processes related to the process of
motor response inhibition itself are normalized during treatment. The
few studies that have examined neurophysiological changes associated
with neurofeedback focussed on mechanisms that were actually trained
during the respective neurofeedback protocols (Gevensleben et al.,
2009; Janssen et al., 2016a, 2016b; Wangler et al., 2011). For a broader
assessment of NF effects it is important to consider neurophysiological
processes that are not equal to the trained neurofeedback parameters
but represent distinct and established correlates of the behaviour or
function to be improved during treatment. To the best of our knowl-
edge, only one study has so far demonstrated a reliable effect of the
applied neurofeedback protocol at the behavioral level and a corre-
sponding improvement on specific neurophysiological mechanisms (i.e.
modulations of the Nogo-P3) that does not reflect a directly trained
neurophysiological parameter (Bluschke et al., 2016a). Studies com-
paring NF and MPH effects using neurophysiological methods at the
important inhibitory control dimension in AD(H)D either use no stan-
dardized neurofeedback training protocol with a consistent target fre-
quency and electrode for all treated patients (Ogrim and Hestad, 2013),
or only provide limited data on changes at the behavioral level con-
sistent with changes at the neurophysiological level (Geladé et al.,
2018; Janssen et al., 2016a).
Regarding the neurophysiological mechanisms being modulated by
MPH and NF interventions, it is further important to consider that the
likelihood to detect reliable treatment effects at the neurophysiological
level is significantly compromised when intra-individual variability in
neurophysiological processes is high (Mückschel et al., 2017; Ouyang
et al., 2011, 2015a). The ERP method can only yield accurate insights
into the neurophysiological processes of cognitive functions when there
is little intra-individual variability (Mückschel et al., 2017; Ouyang
et al., 2011, 2015a). This represents a significant problem in the context
of AD(H)D, as this patient group is characterised by high intra-in-
dividual variability on the behavioral (Gmehlin et al., 2014; Henríquez-
Henríquez et al., 2014; Lin et al., 2015; Plessen et al., 2016; Saville
et al., 2015) as well as the neurophysiological level (Alba et al., 2016;
Bluschke et al., 2017, 2018; Gonen-Yaacovi et al., 2016; Lazzaro et al.,
1997). When the issue of a high intra-individual variability is not ac-
counted for, amplitude and latency jitter are confounded and can lead
to non-corresponding ERP and behavioral effects (Ouyang et al., 2017).
This is especially the case for ERP components with longer latencies
(like the P3 ERP component) (Ouyang et al., 2015b, 2017; Verleger
et al., 2014), which are important in the context of response inhibition.
Therefore, we hypothesize that no reliable treatment effects will be
observed using standard ERPs and expect that reliable treatment effects
are only obtained after accounting for intra-individual variability in the
EEG data. Since intra-individual variability in EEG data can also bias
source localization results (Bodmer et al., 2018), it is even more im-
portant to account for intra-individual variability when aiming to
compare the effects of MPH and NF on a system-neurophysiological
level. To do so, we apply residue iteration decomposition (RIDE)
(Ouyang et al., 2011, 2015a). RIDE decomposes neurophysiological
data based on timing and timing variability and calculates three func-
tionally distinct component clusters (Ouyang et al., 2011, 2015a). The
S-cluster refers to stimulus-related processes (like perception and at-
tention), the R-cluster refers to response-related processes (like motor
preparation/execution) and the C-cluster refers to intermediate pro-
cesses between S and R (like response selection) (Ouyang et al., 2017,
2011). It has been shown that the C-cluster is modulated during the
inhibition of responses and is assumed to reflect processes similar to the
(Nogo)-P3; i.e. a ‘braking function’, or a mechanism that is important
for the inhibition of automated response tendencies (Bluschke et al.,
2016a; Bodmer et al., 2018; Chmielewski et al., 2018; Friedrich et al.,
2018; Mückschel et al., 2017; Ouyang et al., 2015b). Neuroanatomi-
cally, this braking function has specifically been attributed to the right
inferior frontal cortex and its subcortical projection to the subthalamic
nucleus (Aron et al., 2015, 2014; Gillies and Willshaw, 1998). This
behavioral brake has been suggested to be switched on when it is ne-
cessary to stop or pause an action and can be triggered by external
signals and internal goals (Aron et al., 2014; Bianco et al., 2017). The
braking function has been suggested to be weakened in patients with
ADHD, leading to problems in situations in which actions need to be
stopped based on exogenous or endogenous stimuli (Aron et al., 2014).
This represents a clear connection to the increased impulsivity and
response inhibition deficits frequently observed in these patients on the
behavioral level. Conversely, the C-cluster has most consistently been
shown to be modulated during response inhibition processes in the P3
time window, even though some effects are also reported during sti-
mulus-related processes reflected by the S-cluster (Chmielewski et al.,
2018; Mückschel et al., 2017). Therefore, and because the C-cluster has
been shown to best reflect differences in response inhibition mechan-
isms between AD(H)D subtypes (Bluschke et al., 2017), we hypothesize
that effects of MPH or NF treatment on response inhibition should be
reflected by C-cluster modulations in the P3 time window. No or much
weaker effects are expected in the S-cluster. We hypothesize that acti-
vation in the C-cluster will be more pronounced and/or occur earlier
after MPH/NF treatment. At the behavioral level we expect that the rate
of false alarms will decrease due to MPH/NF treatment. From a func-
tional neuroanatomical perspective, the medial frontal cortex and in-
ferior parietal cortices have been shown to reflect modulations in the C-
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cluster (Bodmer et al., 2018; Friedrich et al., 2018, 2017) and to re-
present neuroanatomical correlates of the braking function underlying
response inhibition (Aron et al., 2015, 2014). Functions of the medial
frontal cortex are strongly modulated by the meso-corticolimbic system,
which is dominated by D2 receptors (Nieoullon, 2002). MPH prolongs
the time during which dopamine is available in the synaptic cleft and
entails a stronger dopamine D2 receptor activation (Volkow et al.,
2005; Volz et al., 2008). In contrast to the medial frontal cortex, par-
ietal areas show a much less dense dopaminergic innervation
(Nieoullon, 2002). We therefore hypothesize that (inferior) parietal
areas are less important for the effects of MPH treatment on response
inhibition.
2. Materials and methods
2.1. A-priori sample size estimation
In a previous study on the effects of NF on response inhibition in AD
(H)D it has been shown that the effect size of the treatment was partial
eta squared (ηp2) = 0.1 (Bluschke et al., 2016a). We therefore used this
estimate to calculate the required sample size in the current study to
detect an effect of treatment with a power of at least 95%. The power
calculation using G*Power revealed a total sample size of N = 39; i.e.
N = 13 patients per group (MPH, NF and waiting list control). How-
ever, as outlined below, a total sample of N = 61 was enrolled in the
study; i.e. N~20 per group.
2.2. Sample description
Only patients in whom AD(H)D diagnoses had been determined
according to standard clinical guidelines by a team of experienced child
and adolescent psychiatrists and psychologists (incl. family and school
interviews and questionnaires, IQ and attention testing, exclusion of
possible somatic differential diagnoses via blood analyses, EEG,
audiometry and vision testing) were included in the study. All partici-
pants fulfilled criteria for AD(H)D according to ICD-10 (F90.0, F90.1 or
F98.8). Patients with additional severe or acute psychiatric comorbid-
ities in their clinical history (e.g. autism, tics, depressive episode etc.)
were excluded from the study. N = 20 patients (18 male,
9.7 ± 1.9 years, IQ: 98.7 ± 12.2) were included in the MPH group. T1
testing took place before the first medication intake. T2 testing took
place 8 weeks after the first intake. N = 23 patients (all male,
10.2 ± 1.2 years, IQ: 101.3 ± 12.2) participated in an 8-week theta/
beta neurofeedback training. N = 18 patients were included in a
waiting list control (WLC) group (15 male, 11.1 ± 2.0 years, IQ:
98.8 ± 11.6). In this group, any ongoing treatment for AD(H)D re-
mained consistent and no new interventions were initiated during Some
patients from the NF and WLC group (NF: n = 11; WLC: n = 8) were
taking AD(H)D medication consistently throughout the course of the
study, with no changes occurring between time point T1 and T2. This
could therefore not affect performance differences between T1 and T2.
The administered medications were heterogeneous and included im-
mediate or extended release methylphenidate (NF: n = 9; WLC: n = 6),
atomoxetine (NF: n = 1; WLC: n = 1) and lisdexamphetamine (NF:
n = 1; WLC: n = 1). Please refer to the discussion section for a further
elaboration on this aspect.
The three groups differed significantly in regards to age (F
(2,58) = 4.4, p = .02) with participants in the MPH group being sig-
nificantly younger than the waiting list control group (p = .016). Based
on this age difference, the factor Age was included as a covariate in all
further analyses. There were no significant group differences in IQ (F
(2,58) = 0.28., p = .75). In the AD(H)D Symptom Checklist (Döpfner
et al., 2008) parents rated their children on a scale of 0 (no problems) to
3 (severe problems) in regards to AD(H)D core symptoms. No group
differences were found concerning inattention (F(2,56) = 0.07,
p = .93) (MPH group:2.0 ± 0.74; neurofeedback group: 1.9 ± 0.65,
waiting list controls: 2.0 ± 0.86 (average raw scores)). There were no
differences regarding hyperactivity scores (F(2,57) = 0.04; p = .96)
(MPH group: 1.15 ± 0.81, neurofeedback group: 1.1 ± 0.77, waiting
list controls: 1.1 ± 0.89 (average raw scores)) and impulsivity (F
(2,56) = 0.24; p = .79) (MPH group: 1.7 ± 0.89, neurofeedback
group: 1.7 ± 0.69, waiting list controls: 1.5 ± 1.0 (average raw
scores). All participants were right-handed and there was no difference
in the degree of handedness (p > .6). All subjects and their parents or
legal guardians provided informed written consent according to the
Declaration of Helsinki and the study was approved by the local ethics
committee of the Medical Faculty of the TU Dresden.
2.3. Medication with methylphenidate
All patients included in the MPH group started the intake of me-
thylphenidate immediately after T1 testing. Initially, all patients re-
ceived a low dose of immediate release methylphenidate and switched
to extended-release MPH during the course of treatment. According to
clinical guidelines, this dose was increased until i) a significant and
satisfactory symptom reduction was reported by parents or ii) the target
dose of 1 mg/kg body weight had been reached. Final doses ranged
from 10 mg to 40 mg extended-release MPH per day.
2.4. Neurofeedback protocol
Theta/beta-ratio neurofeedback training took place in two weekly
sessions (1 h each) over a period of 8 weeks. During the course of the
training, patients were trained to downregulate theta power (4–8 Hz)
and to upregulate beta power (13–20 Hz) which were recorded at
electrode Cz. Electrodes above and below the left eye were used to
record eye movements and to correct for motion artifacts since these
could alter the results if not accounted for. The reference electrode was
placed on the left mastoid and an electrode on the forehead was used as
the ground electrode. Theta and beta frequency ranges were presented
to participants via a custom-made software (“Self-regulation and
Attention Management” (“SAM”), University of Erlangen). Time inter-
vals containing artifacts occurring as a result of excessive movement
were discarded online and were not included in the feedback proce-
dure. In case of excessive movements, children were shown a sad smiley
face, reminding them to reduce movements. A two-minute interval was
used for to record theta and beta power at rest at the beginning of each
session (baseline). During the training, children were able to move a
cartoon character or car on the screen by regulating the frequencies in
the required direction (immediate feedback). Within the animation,
frequencies were also shown to the children via moving bars on the
screen. During each session 3–6 neurofeedback blocks were conducted,
each lasting from 5 to 10 min. From session 4–5 onwards, transfer
blocks were introduced in which children were given a task (e.g. at-
tention games, reading, school work) and were required to perform it
without directly seeing feedback on the screen. In these cases, they
received delayed feedback about their ability to regulate the recorded
oscillations in the desired direction. After every training block (with
immediate or delayed feedback), performance was reviewed with the
participant. In adherence to standard protocols (Gevensleben et al.,
2010, 2009), neurofeedback training was supplemented by elements of
behavioral therapy, including psychoeducation, the development of
attentional strategies, homework and a token system.
2.5. Task
A standard Go/Nogo task was used to examine response inhibition
performance (Beste et al., 2011; Chmielewski et al., 2015) at time
points T1 and T2. Within the Go/Nogo task, either the word ‘DRÜCK’
(German for ‘PRESS’; Go stimulus) or ‘STOP’ (Nogo stimulus) was
presented for 300 ms in white font on a black background. A motor
response with the right index finger was required as fast as possible (i.e.
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within 500 ms) when seeing the ‘DRÜCK’ stimulus. Participants had to
refrain from responding when seeing the ‘STOP’ stimulus. The inter-
trial interval (ITI) was jittered between 1600 ms and 1800 ms. The
experiment consisted of 248 Go trials and 112 Nogo trials presented in a
pseudo-randomized order. The task lasted approximately 20 min.
2.6. EEG recording and analysis
The EEG was recorded with an equidistant electrode setup from 60
Ag/AgCl electrodes with a sampling rate of 500 Hz (reference at Fpz,
ground electrode at θ = 58, ф = 78). Electrode impedances were kept
below 5 kΩ. Data processing took place analogous to the procedure
described in (Bluschke et al., 2016a): During off-line data processing,
the recorded data was down-sampled to 256 Hz and a band-pass filter
(0.5–20 Hz, slope: 48 db/oct) was applied. Technical artifacts were re-
moved during the manual inspection of the raw data. They were
identified by their shape in the raw EEG data (e.g. gross and sharp
increases in amplitudes over very short time periods; i.e. “offsets” in the
time series data). An independent component analysis was subse-
quently used to detect and remove periodically occurring artifacts
(pulse artifacts, horizontal and vertical eye movements). Data was
segmented (locked) to the onset the Go and Nogo stimuli
(−200 ms–1500 ms). Only trials with correct responses on Go and
without responses on Nogo trials were analysed further. Remaining
artifacts were removed using an automatic artefact rejection procedure
with an amplitude criterion (maximal amplitude: +200 μV, minimal
amplitude: −200 μV) and using a maximal value difference of 200 μV
in a 200 ms interval as well as an activity below 0.5 μV in a 100 ms
period as rejection criteria. A current source density transformation was
used to allow a reference-free evaluation of the EEG data which helps to
find the electrodes showing the strongest effects (Nunez and Pilgreen,
1991). Data were then baseline corrected to a time interval from
−200 ms to 0 ms and segments were averaged for each condition. In a
data-driven approach, single-subject ERP-amplitudes were quantified as
the mean amplitude in a defined time interval. The choice of electrodes
and time windows was validated using a statistical procedure described
in Mückschel et al. (2014), which is as follows: Within each of the vi-
sually detected search intervals (see below), the peak amplitude was
extracted for all electrodes. Each electrode was subsequently compared
against the average of all other electrodes using Bonferroni-correction
for multiple comparisons. Only electrodes that showed significantly
larger mean amplitudes (i.e., negative for N-potentials and positive for
the P-potentials) than the remaining electrodes were selected. This
validation procedure revealed the same electrodes and time windows as
identified by visual inspection. The following electrodes were chosen
for ERP quantification on the basis of the scalp topography: The P1
(105–125 ms) and N1 (190–210 ms) components were measured over
electrode P7, P8, P9 and P10. P2 amplitudes were exported from
electrodes P3 and P4 (290–310 ms). Electrodes FCz and Cz were used to
measure the N2 (290–310 ms). The P3 component was quantified at Cz
and Pz (500–650 ms).
2.7. Residue iteration decomposition (RIDE)
To account for intra-individual variability in the data, residue
iteration decomposition (RIDE) was run using established protocols
(Chmielewski et al., 2018; Mückschel et al., 2017; Ouyang et al., 2015a,
2015b). The RIDE toolbox and manual are available at http://cns.hkbu.
edu.hk/RIDE.htm. It is important to note that the spatial filter proper-
ties of the CSD do not violate assumptions of RIDE since the decom-
position is conducted separately for each single electrode channel
(Ouyang et al., 2015a).
As mentioned, RIDE decomposes the ERP single-trials data into
three clusters that are either correlated to the stimulus onset (S-cluster
or to the response time (R-cluster), as well as a central C-cluster with
variable latency, which is estimated initially and iteratively improved.
However, in a Go/Nogo task the R-cluster cannot reliably be estimated
in Nogo trials due to a low frequency of responding in these trials
(Ouyang et al., 2013). Therefore, the R-cluster was not computed and
only the S-cluster and the C-cluster were calculated as done in previous
studies by our group (Chmielewski et al., 2018; Mückschel et al., 2017).
Full details on the RIDE methods can be found elsewhere (Ouyang
et al., 2011, 2015a). However, briefly, RIDE uses a nested iteration
scheme for latency estimation through which the latency estimation of
the C-cluster is improved. The initial latency of the C-cluster is esti-
mated using a time window function. In an iterative procedure, the S-
cluster is removed, and the latency of the C-cluster is re-estimated based
on a template matching approach. Information about the validity of the
template matching approach used by the RIDE algorithm can be found
elsewhere (Ouyang et al., 2011, 2013, 2015a). During processing, the
initial time window for the estimation of the C-cluster was set to 200 to
700 ms after stimulus onset. The time window is assumed to cover the
range within which each component is supposed to occur (Ouyang
et al., 2015a). The time window for the S-cluster was set to −200 to
400 ms around stimulus onset. The choice of electrodes and time win-
dows to quantify the RIDE clusters were also validated using a statis-
tical procedure described in Mückschel et al. (2014). For the RIDE-
based analysis, the following electrodes were chosen on the basis of the
scalp topography: In the S-cluster, the P1RIDE (105–125 ms) and N1RIDE
(190–210 ms) were measured over electrodes P7, P8, P9 and P10. The
P2 RIDE component (270–290 ms) was quantified at electrodes P3 and
P4. Furthermore, the N2 RIDE component in the S-cluster (380–420 ms)
was measured at electrode Cz. The C-cluster data was used to quantify
activation in the P3 time window (P3 RIDE). Based on visual inspection,
we exported two time windows (460–475 ms and 550–565 ms) at
electrodes Cz and Pz.
2.8. Source localization analysis
To estimate the sources of neurophysiological effects induced by
MPH and NF treatment we used sLORETA (standardized low resolution
brain electromagnetic tomography; (Pascual-Marqui, 2002). sLORETA
provides a single linear solution to the inverse problem without a lo-
calization bias (Marco-Pallarés et al., 2005; Pascual-Marqui, 2002;
Sekihara et al., 2005). There is also evidence from EEG/fMRI and EEG/
TMS studies underlining the validity of the sources estimated using
sLORETA (Dippel and Beste, 2015; Sekihara et al., 2005). For sLORETA,
the intracerebral volume is partitioned into 6239 voxels at 5 mm spatial
resolution. The standardized current density at each voxel is calculated
in a realistic head model using the MNI152 template. Since the standard
ERP data did not reflect reliable effects of treatment and because these
were only seen in the RIDE C-cluster data (please see results section),
only the C-cluster was used. As this study focuses on the modulation of
neurophysiological mechanisms during the inhibition of responses we
(i) contrasted Nogo trials and Go trials within each group and (ii)
contrasted Nogo trials between groups. Comparisons were based on
statistical non-parametric mapping (SnPM) using the sLORETA-built-in
voxel-wise randomization tests with 2500 permutations. The logic of a
randomization test using SnPM (Nichols and Holmes, 2002) is that if
there is no experimental (i.e. group) effect, the labeling of the groups is
arbitrary. Given the null hypothesis that the labellings are arbitrary, the
significance of a statistic expressing the group effect is then assessed by
comparison with a distribution of values obtained when group-mem-
berships are permuted (Nichols and Holmes, 2002). The randomization
exchanges (permutates) the group memberships by changing the group
membership at the level of the individual subjects. Because the method
is non-parametric it does not require Gaussian distribution of the data.
Voxels with significant differences (p < .50, corrected for multiple
comparisons) between contrasted groups were located in the MNI-brain
www.unizh.ch/keyinst/NewLORETA/sLORETA/sLORETA.htm. In the
Figure, regions of critical activations are given in critical t-values. For
the sLORETA procedure and the estimation of the sources underlying
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significant differences in amplitudes of ERP components between
groups/conditions, only the time windows used for RIDE amplitude
quantification were used. It has previously been shown that RIDE does
not distort source localization analyses using sLORETA, since source
localization results based on ERPs and RIDE decomposed data were
highly similar (Chmielewski et al., 2018).
2.9. Statistics
Within the current study design, it is the goal to examine the dif-
ferential effects of the three treatment conditions (between-subjects
factor Group (MPH vs. neurofeedback vs. waiting list status)) across the
two time points (within-subject factor Time Point (T1 vs. T2)).
Especially it is important to examine whether the effects differ with the
experimental demands (i.e. to execute or withhold a response) (within-
subject factors Go/Nogo (Go vs. Nogo)). Albeit complex, this design is
necessary in order to capture all possible effects and any interactions
between them and to test the postulated hypotheses. When necessary,
the factor Electrode was used as an additional within-subject factor in
the analysis of the neurophysiological data. In addition, the P3RIDE
analysis based on the C-cluster also contained the factor Latency (460-
475 ms vs. 550–565 ms). Based on the significant age difference be-
tween the groups (see Sample Description), the factor Age was included
as a covariate in all analyses (i.e. mixed effects ANCOVAs were calcu-
lated). Greenhouse-Geisser correction was applied and post-hoc tests
were Bonferroni-corrected when necessary. One-way ANOVAs and
paired t-tests were used to examine any significant main effects or in-
teractions further. All variables were normally distributed as indicated
by Kolmogorov-Smirnov tests (all z < 1.05; p > .2).
To examine in how far possible lack of effects between the testing
time points was reliable and to quantify the evidence in favor for this
lack of effects (i.e. the null hypothesis), we calculated Bayesian statis-
tics on the basis of the ANOVA results as proposed by Masson (2011)
and Wagenmakers (2007). We present the Bayesian information cri-
terion (BIC) as well as the probability of the null hypothesis being true
on the basis of the obtained data (p(H0|D). The degree of evidence for
the null hypothesis for was classified according to the criteria put for-
ward by Raferty (1995).
3. Results
3.1. Behavioral data
For the descriptive data, the mean and standard error are given.
Concerning the number of false alarms in the Nogo trials (see Fig. 1),
the main effects of Group (F(2,56) = 0.05, p = .95, ηp2 = 0.002) and
Time Point (F(1, 56) = 2.2, p = .2, ηp2 = 0.04) were not significant.
However, we found a significant interaction between Group and Time
point (F(2,56) = 3.8, p = .029, ηp2 = 0.12). The obtained effect size
ηp2 = 0.12 is well in line with the effects assumed in the power analysis
and is also in line with previous data on NF effects on inhibitory control
in AD(H)D (Bluschke et al., 2016b). A post-hoc power calculation using
G*Power revealed that the achieved power for this interaction effect
was 99%. Within the waiting list control group, we found no differences
between testing at T1 (47.1% ± 5.9) and T2 (48.6% ± 5.5) (F
(1,17) = 0.14, p = .7, ηp2 = 0.008). Bayesian statistics provide further
evidence for the null hypothesis in this case (ΔBIC = 2.74, p
(H0|D) = 0.80). After initiation of treatment with MPH (time point T2),
participants committed significantly fewer false alarms (42.7% ± 5.4)
in Nogo trials than at time point T1 (54.4% ± 4.5) (F(1,19) = 6.8,
p = .02). After neurofeedback, a similar pattern emerged. These parti-
cipants committed significantly fewer errors on Nogo trials at T2
(43.4% ± 4.9) than at T1 (50.4% ± 5.3) (F(1,22) = 6.4, p = .02).
Importantly, the magnitude of change between time points T1 and T2
did not differ significantly between the patients treated with MPH
(−13.1% ± 5.2) and those treated with neurofeedback
Fig. 1. Box plots showing median (continuous line), mean (dashed line) and
distribution of Nogo false alarms, Go hits and Go reaction times for the three
examined groups at both testing time points (MPH = patients treated with me-
thylphenidate, NF = patients treated with neurofeedback, WLC = waiting list
controls). Boxes span from the 25th to the 75th percentile. Whiskers show data
range up to 1.5 box lengths around the box. ○ indicate data points outside of this
range. * indicate significant differences between time points (all p < .002). All
other comparisons between the two time points were not significant.
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(−7.8% ± 3.1) (F(1,42) = 0.85, p = .36). This is also supported by
the Bayesian analysis providing positive evidence that the degree of
change in false alarm rates as an effect of treatment was not different
between NF and the MPH group (ΔBIC = 2.89, p(H0|D) = 0.81).
In terms of correct response to Go stimuli (see Fig. 1), no significant
differences were found between time points for either the patients
treated with MPH (T1: 78.1% ± 7.6, T2: 84.6% ± 6.7), those taking
part in the neurofeedback intervention (T1: 94.5% ± 5.6, T2:
95.2% ± 6.1) or the waiting list controls (T1: 96.1% ± 3.8, T2:
95.4 ± 7.1) (Group * Time Point: F(2,56) = 0.49, p = .62,
ηp2 = 0.02). The main effect of Time Point was also not significant (F
(1,56) = 0.3, p = .6, ηp2 < 0.01). There was, however, a main effect of
Group (F(2,56) = 4.4, p = .02, ηp2 = 0.14) with the MPH group gen-
erally giving significantly fewer correct responses compared to the
neurofeedback group (p = .02) but not compared to the waiting list
controls (p = .08). Waiting list controls and patients taking part in
neurofeedback did not differ from each other significantly in regards to
correct Go responses (p ≥ .99).
Reaction times (RTs) in Go trials (see Fig. 1) did not differ sig-
nificantly between testing at T1 (MPH: 467 ± 21.8 ms; neurofeedback:
470 ± 19 ms; waiting list: 430 ± 19 ms) and T2 (MPH: 441 ± 18,
neurofeedback: 467 ± 16 ms, waiting list: 432 ± 16 ms) (Group *
Time Point: F(2,56) = 0.28, p = .75, ηp2 = 0.01). There were also no
main effects of Group (F(2,56) = 0.6, p = .55, ηp2 = 0.02) or Time
Point (F(2,56) = 2.9, p = .09, ηp2 = 0.05). Further, we also examined
intraindividual variability of the Go reaction times. Here, we found a
significant main effect of Time Point (F(1,56) = 12.9, p = .001,
ηp2 = 0.18) showing generally larger variability at T1 than at T2 (see
below). The main effect of Group was not significant (F(2,56) = 1.8,
p = .17, ηp2 = 0.06). Most importantly, we found a significant Group *
Time Point interaction (F(2,56) = 5.5, p = .007, ηp2 = 0.16). Ex-
amining the change between T1 and T2 separately for all three groups,
we found a significant difference within the patients with MPH (F
(1,19) = 19.1; p < .001; ηp2 = 0.5) (T1: 239 ± 96 ms; T2:
171 ± 69 ms). This difference was not significant within the patients
treated with NF (F(1,22) = 1.1; p = .3; ηp2 = 0.05; T1: 204 ± 75 ms;
T2: 189 ± 62 ms) or in the waiting list controls (F(1,17) = 0.2;
p = .65; ηp2 = 0.01; T1: 168 ± 56 ms; T2: 162 ± 76 ms).
In summary, we thus found specific improvements in the ability to
inhibit prepotent responses in the Nogo trials in the patients treated
with MPH and in those taking part in neurofeedback. The magnitude of
improvement did not differ between these groups. No such changes
were observed in the waiting list controls or in regards to performance
or speed in the Go trials.
3.2. Neurophysiological data
3.2.1. Standard ERP analysis
P1 and N1 components for the three groups, both time points and
for Go and Nogo trials are shown in Fig. 2A. There were no significant
main effects or interactions concerning P1 amplitude (all F < 1.6, all
p > .16, all ηp2 < 0.05). Concerning the N1 amplitude, we found a
main effect of GoNogo (F(1,56) = 11.4, p = .001, ηp2 = 0.17). The N1
component in Nogo trials (−59.4 ± 4.0 μV/m2) was significantly more
pronounced than in Go trials (−52.6 ± 3.7 μV/m2). All other main
effects and interactions were not significant (all F < 3.2, all p > .08,
all ηp2 < 0.06). The P2 ERP-components for the three groups, both
time points and for Go and Nogo trials are shown in Fig. 2B. There were
no significant main effects or interactions (all F < 1.8, all p > .18, all
ηp2 < 0.03). The N2 and P3 components for all three groups, both time
points and for Go and Nogo trials are shown in Figs. 2C and 2D. We
found no significant main effects or interactions (N2: all F < 2.9, all
p > .07, all ηp2 < 0.07; P3: all F < 2.7, all p > .08, all ηp2 < 0.08).
3.2.2. RIDE analysis
3.2.2.1. S-Cluster. Components in the P1-time window (P1RIDE) and
N1-time window (N1 RIDE) for the three groups, both time points and for
Go and Nogo trials are shown in Fig. 3A.
There were no significant main effects or interactions concerning
the P1RIDE amplitude (all F < 2.5, all p > .07, all ηp2 < 0.12).
Concerning the N1RIDE amplitude, we found a main effect of GoNogo (F
(1,56) = 9.7, p = .003, ηp2 = 0.15), showing that the N1RIDE compo-
nent was larger in Nogo trials (−60.6 ± 3.7 μV/m2) than in Go trials
(−54.4 ± 3.8 μV/m2). All other main effects and interactions were not
significant (all F < 2.2, all p > .15, all ηp2 < 0.04).
The component in the P2-time window (P2 RIDE) for the three
groups, both time points and for Go and Nogo trials is shown in Fig. 3B.
There were no significant main effects or interactions (all F < 1.6, all
p > .2, all ηp2 < 0.06). The waveform of the S-cluster in the N2-time
window (N2RIDE) for both groups and for Go and Nogo trials is shown in
Fig. 3C. The analyses of the N2RIDE in the S-cluster revealed a main
effect of the factor GoNogo (F(1,56) = 5.4, p = .024, ηp2 = 0.09), with
larger (i.e. more negative) amplitudes in Nogo (−13.9 ± 2.9 μV/m2)
than in Go trials (−7.4 ± 1.8 μV/m2). No other main effects or inter-
actions (all F < 2.1, all p > .13, all ηp2 < 0.07) were significant.
3.2.2.2. C-Cluster. The waveform of the C-cluster in the P3-time
window (P3RIDE) both groups and for Go and Nogo trials is shown in
Fig. 4A and B.
Concerning the P3RIDE amplitude in the C-Cluster, we found a sig-
nificant main effect of GoNogo (F(1,56) = 71.4, p ≤ .001, ηp2 = 0.6),
indicating that irrespective of all other factors, P3RIDE amplitudes were
always larger in Nogo (25.9 ± 2.5 μV/m2) than in Go trials
(9.3 ± 1.6 μV/m2). Most importantly, there was a significant 5-way
interaction of Group * Time Point * GoNogo * Electrode * Latency
window (F(2, 56) = 3.9, p = .025, ηp2 = 0.12). At this point it is im-
portant to note that even though the a-priori power estimation did not
consider the inclusion of the factors “electrode” and “latency window”
in the statistical model, the observed power of the effect is still very
high. As indicated, the effect size of this interaction was ηp2 = 0.12.
Calculating a post-hoc power analysis using this parameter revealed
that the observed power is still above 91%. This underlines that the
effect is reliable. To examine this interaction in more detail, additional
ANOVAs were conducted to examine which group (i.e. intervention
form) is driving this interaction. Within the patient group treated with
MPH, the interaction of Time Point * GoNogo * Electrode * Latency
window was significant (F(1,19) = 9.3, p = .007, ηp2 = 0.34). Further
ANOVAs were conducted to evaluate which trial type (Go vs. Nogo) is
modulated at what time point, electrode and latency window within the
MPH group: There was significant Time Point * GoNogo * Latency
window interaction at electrode Cz (F(1,19) = 10.2, p = .005,
ηp2 = 0.35), but not at Pz (F(1,19) = 2.5, p = .13, ηp2 = 0.12). At
electrode Cz, we found a significant Time Point * GoNogo interaction at
the earlier (460-475 ms) (F(1, 19) = 8.6, p = .008, ηp2 = 0.31) but not
at the later latency window (550-565 ms) (F(1,19) = 0.02, p = .9,
ηp2 = 0.001). For the earlier latency window, the main effect of Time
Point was only significant in the case of Nogo trials (F(1,19) = 5.2,
p = .04, ηp2 = 0.21), indicating significantly higher P3RIDE amplitudes
after (46.3 ± 11.4 μV/m2) compared to before (22.3 ± 10.2 μV/m2)
MPH treatment. This was not the case when examining Go trials (F
(1,19) = 0.98, p = .33, ηp2 = 0.05) (T1: 12.2 ± 5.8 μV/m2; T2:
6.3 ± 5.6 μV/m2). Taken together, these analyses show that activation
in the C-cluster becomes larger in Nogo trials after MPH administration
at electrode Cz in the earlier time window. The sLORETA analysis
(Fig. 4) revealed activation differences in the medial frontal cortex and
the anterior cingulate cortex (ACC) (BA24, BA32). For the significant
results in the above-mentioned consecutive ANOVAs, post-hoc power
calculations showed that the power was always > 90%.
Within the group of patients treated with NF, the interaction of
Time Point * GoNogo * Electrode *Latency window was not. However,
the interaction of Time Point * Electrode * Latency window did reach
statistical significance (F(1, 21) = 5.7; p = .03, ηp2 = 0.21). At
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electrode Cz, we found no significant interactions or main effects in-
volving the factor Time Point (all F < 2.5, all p > .13, ηp2 < 0.1). At
electrode Pz, however, the main effect of Time Point was significant (F
(1,21) = 7.2, p = .014, ηp2 = 0.26), indicating a more pronounced
P3RIDE component after (26.1 ± 3.9 μV/m2) compared to before neu-
rofeedback (13.7 ± 4.8 μV/m2). This effect was independent of trial
type or latency (no interactions involving the factors GoNogo or
Latency, all F < 3.5; all p > .08, ηp2 < 0.14). The sLORETA analysis
contrasting the C-cluster pooled across Go and Nogo trials between
different time points (contrast: pre < post) revealed activation differ-
ences in the medial frontal cortex, but also in the inferior parietal cortex
(BA40) encompassing the temporo-parietal junction (TPJ). No such
interactions showing any T1-T2 differences were significant for the
waiting list control group (all F < 1.5, all p > .24, all ηp2 < 0.08).
For the significant results in the above-mentioned consecutive ANOVAs,
post-hoc power calculations showed that the power was always > 90%.
4. Discussion
In the current study, we directly compared the system-neurophy-
siological mechanisms associated with MPH treatment and theta/beta
neurofeedback training in children with AD(H)D on response inhibition
processes. We focussed on response inhibition, because this ability is of
high clinical relevance in AD(H)D (Bluschke et al., 2016a; Paul-
Jordanov et al., 2010; Pliszka et al., 2007; Seifert et al., 2003). Re-
sponse inhibition can mostly be examined in tasks investigating re-
sponse inhibition like the Go/Nogo task, and neurophysiological
methods like EEG/ERP pick up neurophysiological processes associated
with response inhibition. As an important methodological aspect not
considered in any previously published study on MPH and/or NF effects
Fig. 2. Stimulus-locked waveforms (current source density) and topographic maps (for Nogo trials only) for A) P1/N1, B) P2, C) N2 and D) P3 components, depicted
for Go and Nogo trials, for both time points (T1 = baseline testing, T2 = testing after 8 weeks of intervention/waiting list status) and for all three experimental
groups (MPH = patients treated with methylphenidate; NF = patients treated with neurofeedback; WLC = patients included as waiting list controls). Point 0 denotes
Go/Nogo stimulus onset. In the topographic maps (shown only for Nogo trials), blue denotes negative deflections whereas red denotes positive ones.
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in AD(H)D, we accounted for intra-individual variability in the EEG
data since this may bias the evaluation of neurophysiological me-
chanisms associated with NF and MPH treatment effects.
On the behavioral level, response inhibition in the applied Go/Nogo
task significantly improved in patients treated with MPH and patients
treated with NF; i.e. the rate of false alarms in Nogo trials was sig-
nificantly reduced at time point T2 (post treatment), compared to T1
(pre treatment). Response inhibition improved to a similar degree in
both the groups and the degree of change observed for the NF inter-
vention was comparable to other data (Bluschke et al., 2016). No
changes were observed in the waiting list controls. This is also sup-
ported by a Bayesian analysis of the data showing that there was strong
evidence in favor for the null hypothesis, i.e. the degree of change in
false alarm rates between T1 and T2 was the same in MPH and NF
intervention. This is especially important to consider because the a-
priori power analysis shows that the study design was sufficiently
powered. Furthermore, we found a significant reduction of Go reaction
time variability in patients treated with MPH but not those treated with
NF or included as waiting list controls. Thus, NF is not as effective in
reducing reaction time variability as it is the case for MPH. This could
be explained by the direct influence of MPH on (particularly tonic as-
pects of) the dopaminergic system (Badgaiyan et al., 2015). This result
shows that it is important to account for intraindividual variability
when examining the neurophysiological data, which was the focus of
this study. Indeed, for the neurophysiological level, the data suggest
that MPH and NF target different neurophysiological mechanisms:
No changes occurred in earlier components such as P1, N1, P2 and
N2, when analysing standard ERPs or in regards to the waiting list
controls. The same was the case for the S-cluster data in the time
windows of the P1, N1, P2 and N2. The finding that no reliable effects
explain the results at the behavioral level very likely reflects issues
related to the intra-individual variability of the EEG data, which is
known to be high in AD(H)D (Gmehlin et al., 2014; Henríquez-
Henríquez et al., 2014; Lin et al., 2015; Plessen et al., 2016; Saville
et al., 2015) also at the neurophysiological level (Alba et al., 2016;
Bluschke et al., 2017, 2018; Gonen-Yaacovi et al., 2016; Lazzaro et al.,
1997). The finding that the S-cluster data did still not reveal effects
explaining the behavioral data suggests that perceptual and attentional
selection processes, known to play an important role in response in-
hibition (Bodmer and Beste, 2017; Friedrich et al., 2018; Stock et al.,
2016), are not modulated and do not underlie MPH- and NF-induced
performance increases in behavioral inhibition. Notably, the C-cluster
data reflected interactive effects which can explain the MPH and NF
effects at the behavioral level, and post-hoc power analyses revealed
that the effects are reliable because the power was above 95%:
For the MPH group it is shown that the C-cluster was larger in Nogo
trials after treatment, while no effects were evident in Go trials. During
Nogo-trials, the Nogo-P3 and the C-cluster have been suggested to
Fig. 3. Stimulus-locked waveforms (current source density) and topographic maps (for Nogo trials only) for activation in the RIDE S-Cluster. Figure shows A) P1RIDE/
N1 RIDE, B) P2 RIDE and C) N2 RIDE component for Go and Nogo trials, for both time points (T1 = baseline testing, T2 = testing after 8 weeks of intervention/waiting
list status) and for all three experimental groups (MPH = patients treated with methylphenidate; NF = patients treated with neurofeedback; WLC = patients in-
cluded as waiting list controls). Point 0 denotes Go/Nogo stimulus onset. In the topographic maps (shown only for Nogo trials), blue denotes negative deflections
whereas red denotes positive ones.
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reflect a ‘braking function’, or a mechanism that is important when
inhibiting automated response tendencies (Bluschke et al., 2016a;
Bodmer et al., 2018; Chmielewski et al., 2018; Friedrich et al., 2018;
Mückschel et al., 2017; Ouyang et al., 2015a). These mechanisms seem
to become stronger as an effect of MPH treatment. Treatment with MPH
thus seems to reduce the postulated weakness of the braking function in
ADHD (Aron et al., 2014). From a neurobiological perspective, MPH
prolongs the time during which dopamine is available in the synaptic
cleft and leads to a stronger dopamine D2 receptor activation (Volkow
et al., 2005; Volz et al., 2008). Yet, it needs to be noted that the nor-
epinephrine system is also affected by MPH. Notably, it has been shown
that the dopamine D2 receptors and the meso-corticolimbic dopamine
system strongly modulate processes reflected by the Nogo-P3 (Beste
et al., 2016, 2010). Other lines of evidence show that dopamine D2
receptor agonists improve inhibitory control in healthy subjects
(Nandam et al., 2013) and that blocking D2 receptors negatively affects
inhibitory control in animals (Eagle et al., 2011). The source localiza-
tion results for the current study show that MPH-induced modulations
in C-cluster activation during Nogo trials were associated with activa-
tion differences in the anterior cingulate cortex (ACC; BA24, BA32).
The ACC is modulated by the meso-corticolimbic system (dominated by
D2 receptors) (Nieoullon, 2002). Considering findings that the C-cluster
during Nogo trials in the time window between 400 and 600 ms after
target stimulus presentation reflects processes of the Nogo-P3 (Bluschke
et al., 2016a; Bodmer et al., 2018; Chmielewski et al., 2018; Friedrich
et al., 2018; Mückschel et al., 2017; Ouyang et al., 2015a), the phar-
macological effects of MPH and the obtained effects of MPH in the
current study can be interpreted as an enhancement of the braking
processes in anterior cingulate structures possibly reflecting an effect of
the modulation of the meso-corticolimbic dopamine system. This en-
hances behavioral inhibition in patients with AD(H)D.
Importantly, the positive effects of NF on inhibitory control
Fig. 4. Stimulus-locked waveforms (current source density) and topographic maps (for Nogo trials only) for activation in the RIDE C-Cluster. Figure shows A) the
P3RIDE at electrode Cz and B) the P3 RIDE at electrode Pz for Go and Nogo trials, for both time points (T1 = baseline testing, T2 = testing after 8 weeks of inter-
vention/waiting list status) and for all three experimental groups (MPH = patients treated with methylphenidate; NF = patients treated with neurofeedback;
WLC = patients included as waiting list controls). Point 0 denotes Go/Nogo stimulus onset. In the topographic maps (shown only for Nogo trials), blue denotes
negative deflections whereas red denotes positive ones. sLORETA images show contrasts in Nogo trials between the two time points for the two intervention groups
and reveal activation differences in the medial frontal cortex and the anterior cingulate cortex (ACC) (BA24, BA32) for the patients treated with MPH. For the patients
treated with NF, sLORETA showed activation differences in the medial frontal cortex, but also in the inferior parietal cortex (BA40) encompassing the temporo-
parietal junction (TPJ). Colours indicate the critical t-value (corrected for multiple comparison using SnPM).
A. Bluschke et al. NeuroImage: Clinical 20 (2018) 1191–1203
1199
performance are based on neurophysiological mechanisms different to
the effects of MPH. In contrast to MPH, the effects of NF were less
specific on the neurophysiological level because NF-induced modula-
tions of the C-cluster were evident in Go and Nogo trials. However,
since behavioral performance in Go trials (RT and error rate) was not
modulated between T1 and T2, the induced effects in Go trials are
unlikely to be important for the behavioral effects to emerge.
Nevertheless, the source localization analysis also indicates that treat-
ment with NF modulates different processes than treatment with MPH
since in addition to medial frontal areas, inferior parietal areas (BA40,
TPJ) were also found to be associated with NF-induced modulations of
the C-cluster amplitudes. A modulation of medial frontal areas asso-
ciated with the Nogo-P3 was also obtained in another study examining
the effects of NF using a Go/Nogo task (Bluschke et al., 2016a). How-
ever, this study did not account for intra-individual variability in the
data. When this was done, other recent studies examining response
inhibition processes more generally already found that modulations in
the C-cluster amplitude are associated with inferior parietal areas and
the medial frontal cortex (Bodmer et al., 2018; Friedrich et al., 2018,
2017). To understand the relevance of the obtained modulations of
inferior parietal areas in the current study, it is important to consider
that the applied neurofeedback protocol combined a modulation in the
theta frequency band and the beta frequency band. Even though the NF
effects can therefore not be attributed to the action of a particular
frequency band, it is important to stress that theta oscillations asso-
ciated with inhibitory control are mediated via brain regions encom-
passing the left temporo-parietal junction (TPJ, BA40) (Dippel et al.,
2016). The TPJ has been suggested to processes task-relevant stimuli to
update internal representations of the environmental context to initiate
appropriate actions (Geng and Vossel, 2013). Theta oscillations have
also been suggested to encode a “surprise signal” (Cavanagh and Frank,
2014). This putative function of the theta oscillations fits well into the
possible functional role of the TPJ (Geng and Vossel, 2013) and the Go/
Nogo paradigm applied in the current study which contained more Go-
than Nogo-trials which involve the processing of a “surprise signal”.
Crucially, beta oscillations have also been suggested to be important for
the stabilisation of processes protecting cognitive operations against
interfering events (Engel and Fries, 2010). Together, it is possible that
the applied NF protocol may have modulated these processes making it
possible to update and stabilize mental representations in order to in-
itiate appropriate actions or inhibitory control. This may particularly be
the case when these processes are ‘surprising’. Together, it becomes
apparent that MPH and NF have similar effects on behavioral inhibition
performance, but the underlying mechanisms are different. In parti-
cular, the treatment with NF is likely to modulate neural processes
beyond those affected by MPH. This interpretation is further evidenced
by the source localization findings showing that medial frontal areas
are modulated by both interventions, while parietal areas are only af-
fected by NF.
5. Implications
While the neurophysiological mechanisms associated with treat-
ment effects seem to be different between MPH and NF interventions,
the behavioral results suggest that both interventions are equally ef-
fective to treat inhibitory deficits as examined using the Go/Nogo task
in the current study. This is of high clinical relevance because it has
been shown that a significant proportion of patients discontinue MPH
treatment for several reasons and prefer non-pharmacological treat-
ment approaches (Dosreis et al., 2017; Garbe et al., 2012; Ng et al.,
2017; Schatz et al., 2015). The finding that both interventions seem to
target complementary cognitive-neurophysiological processes and
functional neuroanatomical structures may provide the basis for a
combined MPH + NF intervention. Since MPH and NF target different
mechanisms, this may explain why combined MPH + NF interventions
have been suggested to be more effective when treating executive
dysfunctions in AD(H)D than one intervention form alone (González-
Castro et al., 2015). It is possible that medial frontal mechanisms, tar-
geted by MPH, and parietal mechanisms, targeted by NF, may have
additive effects in terms of efficacy. Considering that the NF effects
seem to be associated with parietal areas, it may be possible to further
boost the effects of a neurofeedback treatment by including brain sti-
mulation methods during the NF intervention. Especially transcranial
direct current stimulation (tDCS) could be useful in this regard as there
is evidence that this technique improves AD(H)D symptoms and cog-
nitive functions (Rubia, 2018).
6. Limitations
One limitation is that the allocation of patients to the different in-
tervention groups y was not randomized in the current study. However,
this study did not intend to examine the effectiveness of the NF and
MPH treatment approaches per se since these have been demonstrated
previously (refer introduction section). The goal of this study was to
examine the neural mechanisms targeted by these interventions and to
evaluate any differences between them. While it may also be argued
that the sample size is moderate and may limit generalizability, it is
important to stress that the sample size was based on power calcula-
tions using estimates of published data and that the obtained effect sizes
are in line with that. Post-hoc power analysis of the actually employed
statistical model further revealed that the study is sufficiently powered.
This, together with the Bayesian analysis of the data, also allows reli-
able conclusions about aspects of the study that showed no differential
effects between NF and MPH treatments; i.e. that attentional selection
processes were unaffected. It may be argued that the heterogenous
medication profile in the NF group may confound the results. However,
since the medication profile was not changed between T1 and T2, the
effects in the NF at T2 cannot be attributed to the medication effects.
Moreover, the waiting list control group also included subjects with a
similar heterogenous medication profile. The finding that no changes
between T1 and T2 were observed here further underlines that the ef-
fects in the NF group are due to the NF intervention. Yet, especially
considering that implication of the findings that for combined MPH and
NF treatments, further validations of the results are required.
7. Summary
In summary, the study shows that MPH and theta/beta NF treat-
ments increase the ability to inhibit prepotent responses to a similar
extent in patients with AD(H)D. However, the data suggest that MPH
and NF target different neurophysiological mechanisms, especially
when it comes to functional neuroanatomical structures associated with
these effects. Both treatments seem to affect neurophysiological corre-
lates of a ‘braking function’ in medial frontal areas. However, in case of
the NF intervention, inferior parietal areas also are involved, likely
reflecting how efficient internal representations can be updated and
stabilized to initiate appropriate actions. No effects were seen in cor-
relates of perceptual and attentional selection processes. Notably, the
study shows that it is important to account for intra-individual varia-
bility in the neurophysiological data when evaluating MPH/NF treat-
ment effects in AD(H)D at the system-neurophysiological level. This
aspect may also partly explain the diversity of findings in studies on
treatment effects in AD(H)D, especially concerning neurofeedback
treatment effects.
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